Athena | Heart [310]

: Periodic testing is recommended due to reported cases of liver injury.

: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo. ATHENA HEART [310]

Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial : Periodic testing is recommended due to reported

Stop other Class I or III antiarrhythmics (e.g., amiodarone, sotalol) before starting Multaq. Avoid strong (e.g., ketoconazole). ATHENA HEART [310]

The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death.